These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22362269)

  • 1. Current treatment options for metastatic breast cancer: what now?
    Rugo HS; O'Shaughnessy JA; Perez EA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 25):1-16. PubMed ID: 22362269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
    Rugo HS; O'Shaughnessy JA; Perez EA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):1-16. PubMed ID: 22355830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Palliative chemotherapy for metastatic breast cancer with capecitabine].
    Inaba T; Kashiwaba M; Takeda Y; Komatsu H; Tomisawa Y; Takiyama I; Wakabayashi G
    Gan To Kagaku Ryoho; 2009 May; 36(5):769-72. PubMed ID: 19461175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
    Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
    J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
    Oksuzoglu B; Abali H; Hayran M; Yildirim N; Budakoglu B; Zengin N
    Chemotherapy; 2008; 54(5):352-6. PubMed ID: 18728366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination versus sequential single-agent therapy in metastatic breast cancer.
    Miles D; von Minckwitz G; Seidman AD
    Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiogenesis inhibition in the treatment of breast cancer.
    Sledge GW; Rugo HS; Burstein HJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
    Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
    Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.
    Iorfida M; Mazza M
    Future Oncol; 2015; 11(15 Suppl):23-6. PubMed ID: 26235261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
    Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
    Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
    Lopes G; Glück S; Avancha K; Montero AJ
    Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer.
    McDonald F; Miles D
    Int J Clin Pract; 2003; 57(6):530-4. PubMed ID: 12918893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.